全文获取类型
收费全文 | 21060篇 |
免费 | 1659篇 |
国内免费 | 266篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 520篇 |
妇产科学 | 397篇 |
基础医学 | 1006篇 |
口腔科学 | 768篇 |
临床医学 | 2991篇 |
内科学 | 3939篇 |
皮肤病学 | 439篇 |
神经病学 | 864篇 |
特种医学 | 545篇 |
外科学 | 1358篇 |
综合类 | 2030篇 |
现状与发展 | 6篇 |
预防医学 | 4802篇 |
眼科学 | 303篇 |
药学 | 1472篇 |
19篇 | |
中国医学 | 632篇 |
肿瘤学 | 828篇 |
出版年
2024年 | 37篇 |
2023年 | 399篇 |
2022年 | 517篇 |
2021年 | 999篇 |
2020年 | 1209篇 |
2019年 | 903篇 |
2018年 | 903篇 |
2017年 | 784篇 |
2016年 | 803篇 |
2015年 | 697篇 |
2014年 | 1366篇 |
2013年 | 2091篇 |
2012年 | 1064篇 |
2011年 | 1213篇 |
2010年 | 1037篇 |
2009年 | 958篇 |
2008年 | 955篇 |
2007年 | 975篇 |
2006年 | 936篇 |
2005年 | 775篇 |
2004年 | 631篇 |
2003年 | 562篇 |
2002年 | 505篇 |
2001年 | 393篇 |
2000年 | 295篇 |
1999年 | 292篇 |
1998年 | 246篇 |
1997年 | 184篇 |
1996年 | 213篇 |
1995年 | 149篇 |
1994年 | 103篇 |
1993年 | 117篇 |
1992年 | 84篇 |
1991年 | 63篇 |
1990年 | 59篇 |
1989年 | 55篇 |
1988年 | 69篇 |
1987年 | 44篇 |
1986年 | 36篇 |
1985年 | 37篇 |
1984年 | 40篇 |
1983年 | 31篇 |
1982年 | 24篇 |
1981年 | 32篇 |
1980年 | 17篇 |
1979年 | 15篇 |
1978年 | 9篇 |
1977年 | 18篇 |
1976年 | 14篇 |
1975年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 953 毫秒
41.
目的:对采用头皮冠状切口所引发的并发症进行分析,探讨防治策略。方法:对我科2003-01~2006—07应用头皮冠状切口行颅颌面骨折修复重建、颌面部肿瘤切除与缺损修复、先天性颅颌面畸形矫正的221例中发生并发症的40例进行分析总结。结果:18例出现头皮麻木及感觉异常,9例有较宽切口瘢痕,6例出现脱发,4例发生颞窝凹陷,2例发生头皮下血肿,2例出现单侧面神经颞支损伤,1例发生鼻眶区肥厚。结论:头皮冠状切口具有切口隐蔽、面部疤痕不明显,显露充分的优点,但对其并发症也不容忽视。应根据具体情况选择合适的切口类型,术中精细的解剖、神经血管的良好保护以及正确的缝合方法可减少并发症的发生。 相似文献
42.
颈丛阻滞常可引起心率增快 ,血压增高 ,被认为是颈动脉窦及迷走神经被阻滞 ,交感神经活性增强所致 [1 ]。我们采用艾司洛尔预注射的方法 ,抑制颈丛阻滞后的心血管副反应 ,取得了良好的效果 ,现介绍如下。1 临床资料和方法1.1 一般资料 选择 ASA I~ 级 ,择期行甲状腺瘤或囊 相似文献
43.
调整给药时间减轻顺铂肾毒性的研究 总被引:7,自引:0,他引:7
目的 观察不同给药时间对顺铂肾毒性的影响。 方法 1 6例癌症患者分为两组各 8例 ,分别在上午 1 0时或下午 8时静滴 6 0mg m2 顺铂 ,3~ 4周后作第 2周期化疗时交换给药时间 ,以尿 β2 微球蛋白浓度作为肾小管功能改变的指标。 结果 治疗前两组的尿 β2 微球蛋白浓度均在 2 0 0 μg L以下。治疗后 ,上午 1 0时给药组的尿β2 微球蛋白浓度在第 1周期为 4 96± 6 6 μg L ,第 2周期为 5 0 4± 74 μg L ,下午 8时给药组分别为 2 77± 4 3μg L(t=3.6 6 ,P <0 .0 1 )和 2 83± 39μg L(t=3.6 3,P <0 .0 1 )。 结论 不同时间给药对顺铂的肾毒性有显著影响 ,下午 8时给药可明显减轻顺铂的肾毒性。 相似文献
44.
W. A. A. Tjalma M. Arbyn† J. Paavonen‡ T. R. Van Waes & J. J. Bogers§ 《International journal of gynecological cancer》2004,14(5):751-761
Persistent infection with one of the oncogenic human papillomavirus (HPV) types is a necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could become a very rare disease. Two types of HPV vaccines can be distinguished: (i) therapeutic vaccines which induce cellular immunity targeted against epithelial cells infected with HPV and (ii) prophylactic vaccines inducing virus-neutralizing antibodies protecting against new but not against established infections. At present, several vaccines have been developed and tested in clinical trials. The vaccines are generally well tolerated and highly immunogenic. The current clinical data indicate that prophylactic vaccines are very effective against new persistent infections and the development of cervical intraepithelial lesions. The protection is type specific. However, the follow-up of the vaccination trials is still short. The effect of HPV vaccines on future cancer incidence will only be known after decades of follow-up. This article will address the status of recently terminated phase II and currently running phase III trials with prophylactic HPV vaccines. 相似文献
45.
Leslee J. Shaw Romalisa Miranda-Peats Piotr Slomka John Friedman Sean W. Hayes Daniel S. Berman Gary V. Heller Marcin Dada William E. Boden Paul Casperson Robert A. O’Rourke Ronald Schwartz William S. Weintraub David J. Maron Spencer King Koon Teo Pamela Hartigan 《Journal of nuclear cardiology》2006,13(5):685-698
Background Stress gated myocardial perfusion single photon emission computed tomography (gSPECT) is increasingly used before and after
intercurrent therapeutic intervention and is the basis for ongoing evaluation in the Department of Veterans Affairs clinical
outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial.
Methods and Results The COURAGE trial is a North American multicenter randomized clinical trial that enrolled 2287 patients to aggressive medical
therapy vs percutaneous coronary intervention plus aggressive medical therapy. Three COURAGE nuclear substudies have been
designed. The goals of substudy 0 are to examine the diagnostic accuracy of the extent and severity of inducible ischemia
at baseline in COURAGE patients compared with patient symptoms and quantitative coronary angiography and to explore the relationship
between inducible ischemia and the benefit from revascularization when added to medical therapy. Substudy 1 will correlate
the extent and severity of provocative ischemia with the frequency, quality, and instability of recurrent symptoms in postcatheterization
patients. Substudy 2 (n _ 300) will examine the usefulness of sequential gSPECT monitoring 6 to 18 months after therapeutic
intervention. Together, these nuclear substudies will evaluate the role of gSPECT to determine the effectiveness of aggressive
risk-factor modifications, lifestyle interventions, and anti-ischemic medical therapies with or without revascularization
in reducing patients’ ischemic burdens.
Conclusions The unfolding of evidence on the application of gSPECT in trials such as COURAGE defines a new era for nuclear cardiology.
We hope the evidence that emerges from the COURAGE trial will further establish the role of nuclear imaging in the evidence-based
management of patients with stable coronary disease.
The COURAGE trial was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research
and Development in collaboration with the Canadian Institutes of Health Research. Unrestricted research grants were obtained
from Merck & Co; Pfizer Pharmaceuticals; Bristol-Myers Squibb Medical Imaging; Astellas Pharma; Kos Pharmaceuticals; Data
Scope; Astra Zeneca Pharmaceuticals; Astra-Zeneca-Canada; Schering-Plough Coorporation, Ltd; Sanofi-Aventis, Inc; First Horizon;
and GE Healthcare. All industrial funding for this trial was directed through the Department of Veterans Affairs. Additional
funding for this substudy was provided by grants to the Department of Veterans Affairs and Canadian Institutes of Health Research
from Astellas Pharma and Bristol-Myers-Squibb Medical Imaging. 相似文献
46.
Judith D. Goldberg Arnold I. Weiss Kenneth J. Koury 《Journal of clinical periodontology》1986,13(5):411-414
In order to make effective use of the statistical theory of design of clinical trials for chronic diseases such as periodontal disease, certain issues must be considered. Any clinical trial requires that the disease definition be well-specified; that patient eligibility be explicit; that the observation times be explicit; that the duration and endpoint of therapy be specified; that the duration of subsequent followup observation be specified; and that the unit of observation (e.g., tooth, set of teeth, patient) be defined. In a chronic disease, the potential biases that can readily be introduced by self-selection of patients who enter the trial and/or who return for subsequent observation become more important, because subjects are required to remain on treatment and/or observation for prolonged periods. Further, the cyclical nature of some chronic diseases may require special attention to baseline definitions of active disease and disease outcome. These issues are illustrated with examples from clinical trials of hypertension, breast cancer screening, and Polycythemia Vera. Implications for periodontal disease are discussed. 相似文献
47.
固定剂量复合剂在省结核病防治规划中应用的研究 总被引:2,自引:0,他引:2
目的 研究固定剂量复合剂在省结核病防治规划中应用的可行性.方法 将初治涂阳肺结核病人按登记序号单双分入研究组和对照组.用对照研究方法对两组的完成治疗率、治疗效果、治疗依从性和不良反应等情况进行分析.结果 研究组和对照组在性别、年龄、体重、完成治疗率、督导管理方式和治疗依从性等方面差异无显著性(P值均>0.05).研究组的2、3个月未痰菌阴转率和治愈率分别为87.0%、93.5%和93.5%,对照组的2、3个月未痰菌阴转率和治愈率分别为89.4%、93.5%和87.0%,两组间的疗效差异无显著性(P值均>0.05).除因链霉素引起的耳鸣(精确概率法P=0.024)外,两组其他不良反应症状出现的比例都无显著性差异(P值均>0.05).结论 在结核病防治规划中推广应用固定剂量复合剂是可行的. 相似文献
48.
49.
目的 了解2型糖尿病患者住院前及住院期间卒中各危险因素的干预状况,发现临床实践与证据之间的差距,提高临床医生对卒中一级预防的认识,指导今后的临床治疗。方法 本调查为横断面调查研究,回顾性调查167例2型糖尿病患者住院前及住院期间对卒中主要危险因素的干预情况。结果 被调查的患者中,入院前有46.7%的患者有高血压;36.0%的患者有吸烟史;19.8%的患者存在冠状动脉粥样硬化性心脏病,0.6%的患者有心房颤动;23.4%的患者有脂代谢异常。出院前有56.9%的患者被诊断高血压;81.4%的患者存在脂代谢异常。入院前与出院前对血压的药物干预率差异无统计学意义(分别为75.6%及80.0%,P >0.05);入院前后的降脂治疗(分别为25.6%及69.1%,P <0.01)及降糖治疗(分别为82.0%及97.6%,P <0.01)的差异均有统计学意义。结论 2型糖尿病患者院前对危险因素干预的达标率较低,应加强2型糖尿病患者及临床医生对卒中一级预防的认识,提高卒中卒中相关危险因素的干预率。 相似文献
50.